Immunodiagnostics and Vaccine Development at Viravaxx AG gain momentum
Vienna (Austria), Jan 11, 2021. Fast-track development of vaccines against COVID-19 and other infectious diseases are facilitated by microarray-based assays for whole-proteome analysis and vaccine design platforms. Both have been developed by Viravaxx AG, and the company’s recent progress with its SARS-CoV-2 Interaction Assay offered a turning point.
(firmenpresse) - Concomitantly, as of Jan 1, 2021, Viravaxx has recruited Dr. Helmut Brunar as its new CEO. Dr. Brunar brings vast expertise in vaccines, cell-therapies and diagnostic products to the company. Before joining Viravaxx, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. Dr. Brunar will take over from Dr. Rainer Henning, who has made invaluable contributions for establishing the company at the forefront of innovative immunodiagnostics and vaccine development.
The management team is completed with Dr. Frank Stolz, who has been with Viravaxx since its inception. Dr. Stolz is an experienced head of pre-clinical and clinical product development with a successful history of working in biotechnology and in basic research. At Viravaxx, he is responsible for product innovation, process and analytical development. He leads Viravaxx’s preclinical vaccine development and diagnostic platforms.
Viravaxx focuses its activities on hard-to-treat viral infections, such as respiratory syncytial virus (RSV) and rhinovirus (RV), which have resisted vaccination approaches for a long time. To this end, Viravaxx collaborates with Prof. Dr. Rudolf Valenta’s research group at the Medical University of Vienna. The Valenta labs exploit technology to convert non-immunogenic epitopes of surface proteins essential for the virus life cycle to potent immunogens. In addition, the Valenta labs develop multiplexed tools for high resolution serum immune diagnostics.
The cooperation with the Valenta labs puts Viravaxx in a perfect position to strengthen its partnering position with big pharma and biotech. With its marketed - research use only - high-resolution multiplex proteomic chip for whole-genome antigen mapping, its SARS-CoV-2 Interaction Assay and its clinical-stage hepatitis B candidate VVX001 for therapeutic and prophylactic vaccination, Viravaxx is well prepared to participate at the upcoming 39th J.P. Morgan Healthcare Conference. This conference, held virtually for the first time in 2021, is the largest healthcare conference kicking-off the new year.
About Viravaxx
Viravaxx AG is an emerging biopharmaceutical company focused on the development of innovative antiviral vaccines and immunodiagnostics. For the development of vaccines, Viravaxx converts immuno-dominant protein epitopes into potent antigens eliciting a strong IgG antibody response. This technology allows to design vaccines across different serotypes by addressing invariant regions of any antigen required for receptor binding and virus entry. Viravaxx’s lead product is the clinical-stage hepatitis B candidate VVX001 for therapeutic and prophylactic vaccination - currently in clinical phase II.
Contact:
Viravaxx AG
Dr. Helmut Brunar, CEO
Mariannengasse 14/9
1090 Vienna, Austria
T +43 1 7966 296 100
info(at)viravaxx.com
http://www.viravaxx.com
Copy Editing & Distribution
PR&D – Public Relations for Research & Education
Dr. Barbara Bauder
Mariannengasse 8
1090 Vienna, Austria
T +43 1 505 70 44
M +43 664 1576350
bauder(at)prd.at
http://www.prd.at
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2021 - 19:39 Uhr
Sprache: Deutsch
News-ID 627243
Anzahl Zeichen: 3769
contact information:
Contact person: Till C. Jelitto
Town:
Vienna
Phone: +43 01 5050 70 44
Kategorie:
Pharmaceuticals & Biotech
Typ of Press Release: Company
type of sending: don't
Date of sending: 11.01.2021
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Immunodiagnostics and Vaccine Development at Viravaxx AG gain momentum "
steht unter der journalistisch-redaktionellen Verantwortung von
PR&D (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
